SESN [NASD]
Sesen Bio, Inc.
Index- P/E1.65 EPS (ttm)0.24 Insider Own0.10% Shs Outstand199.46M Perf Week-13.13%
Market Cap81.82M Forward P/E- EPS next Y-0.01 Insider Trans0.00% Shs Float198.44M Perf Month-40.76%
Income47.90M PEG- EPS next Q-0.08 Inst Own14.50% Short Float1.92% Perf Quarter-50.93%
Sales20.00M P/S4.09 EPS this Y99.00% Inst Trans-34.68% Short Ratio1.86 Perf Half Y-42.04%
Book/sh0.71 P/B0.55 EPS next Y78.70% ROA21.80% Target Price- Perf Year-49.87%
Cash/sh0.68 P/C0.58 EPS next 5Y- ROE29.50% 52W Range0.37 - 1.47 Perf YTD-52.02%
Dividend- P/FCF- EPS past 5Y-15.10% ROI-0.20% 52W High-73.40% Beta0.73
Dividend %- Quick Ratio4.90 Sales past 5Y-2.40% Gross Margin- 52W Low7.12% ATR0.05
Employees35 Current Ratio4.90 Sales Q/Q- Oper. Margin- RSI (14)23.34 Volatility11.45% 10.12%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.50% Profit Margin- Rel Volume0.40 Prev Close0.38
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume2.04M Price0.39
Recom3.00 SMA20-34.59% SMA50-40.70% SMA200-41.63% Volume820,782 Change2.89%
Aug-16-21Downgrade H.C. Wainwright Buy → Neutral
Jun-11-19Upgrade H.C. Wainwright Neutral → Buy $3
Sep-22-22 05:27AM
Sep-21-22 11:39AM
11:35AM
11:08AM
10:02AM
08:00AM Loading…
08:00AM
Sep-20-22 05:50PM
Sep-19-22 12:15PM
11:58AM
Sep-15-22 12:15PM
Sep-14-22 01:09PM
Sep-13-22 11:24AM
11:18AM
Sep-09-22 12:23PM
12:18PM
09:37AM Loading…
Sep-08-22 09:37AM
Sep-07-22 11:40AM
Sep-06-22 11:09AM
10:39AM
10:34AM
Aug-31-22 10:47AM
Aug-30-22 11:38AM
Aug-26-22 01:21PM
Aug-25-22 12:18PM
Aug-24-22 09:55AM
Aug-19-22 12:20PM
Aug-18-22 12:38PM
Aug-17-22 12:32PM
Aug-15-22 08:56AM
Aug-10-22 03:16PM
11:56AM Loading…
Aug-09-22 11:56AM
Aug-08-22 12:41PM
12:39PM
08:00AM
Jul-27-22 12:00PM
Jul-19-22 12:23PM
Jul-18-22 08:06AM
07:30AM
Jul-05-22 10:16AM
Jun-28-22 10:41AM
10:23AM
Jun-27-22 11:00AM
10:31AM
Jun-24-22 10:08AM
Jun-22-22 09:24AM
Jun-13-22 01:27PM
09:41AM
Jun-10-22 03:30PM
Jun-09-22 08:25AM
Jun-08-22 01:21PM
09:13AM
Jun-07-22 08:51AM
Jun-06-22 02:04PM
Jun-03-22 03:54PM
Jun-02-22 03:26PM
03:20PM
Jun-01-22 02:25PM
02:22PM
09:00AM
May-31-22 02:27PM
10:16AM
10:11AM
May-27-22 10:20AM
09:26AM
May-26-22 10:01AM
May-25-22 08:41AM
08:35AM
01:09AM
May-24-22 09:47AM
May-23-22 10:20AM
10:14AM
May-19-22 08:31AM
May-17-22 09:27AM
09:08AM
May-16-22 02:23PM
09:28AM
May-09-22 08:00AM
May-03-22 08:00AM
Feb-28-22 08:00AM
Feb-17-22 01:59PM
Jan-10-22 08:00AM
Dec-22-21 01:17PM
Dec-09-21 05:13PM
01:09PM
08:00AM
Dec-08-21 09:28AM
Dec-07-21 01:51PM
Dec-01-21 01:04PM
Nov-29-21 08:00AM
Nov-23-21 08:00AM
Nov-16-21 01:13PM
Nov-08-21 09:25AM
08:00AM
Nov-01-21 03:01PM
08:00AM
Oct-22-21 07:32AM
Oct-21-21 07:22AM
Oct-20-21 02:30PM
12:07PM
08:17AM
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.